Rupert Beale

Measuring immunity is important, but it isn’t easy. The most obvious way is to look for the presence of antibodies. But antibodies to what? The virus has many components. Its main entry weapon is known as Spike. This is a large, sugar-coated protein complex that can rip a hole in the membrane of a cell to allow the virus to enter. Block Spike, and you keep the virus out. It’s easy enough to measure antibodies to Spike, but not all of them actually prevent the virus from entering cells. To find out whether the antibodies are doing their job effectively, you have to culture the virus in a high-containment facility, titrate tiny amounts of serum extracted from the test subject’s blood into the virus culture, and demonstrate that the serum blocks the virus. It’s painfully slow. We are working on ways to make these assays faster, easier and more accurate. So are many others, and for once I’m happy when another lab does something better.

In countries where rapid testing and isolation do not happen, the disease will at its peak rapidly overwhelm the ability of hospitals to cope, and the case fatality rate will be much higher. The global case fatality rate is above 3 per cent at the moment, and if – reasonable worst case scenario – 30-70 per cent of the 7.8 billion people on earth are infected, that means between 70 and 165 million deaths. It would be the worst disaster in human history in terms of total lives lost. Nobody expects this, because everyone expects that people will comply with efficient public health measures put in place by responsible governments.

The business​ of science is intensely frustrating. Most experiments fail, most great ideas come to nothing, and most genuine discoveries turn out to be of modest importance. Years of effort can easily be wasted on what turns out to be a mirage. In biology, we usually fail for the dullest of reasons: a test wasn’t as specific as we thought, a wondrous result proved to be a simple...